Cite
HARVARD Citation
Kuo, C. et al. (2018). Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. Therapeutic advances in hematology. pp. 65-78. [Online].